MedTrace Logo

Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers

NCT00225667 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2005-11-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether irbesartan will reduce the rate of recurrent atrial high rate episodes and the development of clinical sustained atrial fibrillation in patients with hypertension and permanent pacemaker.

Conditions

Interventions

DRUG

Irbesartan

Sponsors & Collaborators

Principal Investigators

  • Stuart J. Connolly, MD · McMaster University

  • Jeffrey S Healey, MD · McMaster University

  • Carlos A Morillo, MD · McMaster University

  • Stefan H Hohnloser, MD · J.W. Goethe University, Frankfurt Germany

  • Carsten W Israel, MD · J.W. Goethe University, Frankfurt Germany

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Completion
2007-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225667 on ClinicalTrials.gov